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This work describes the design and synthesis of peptidomimetics for the inhibition of the protein-
protein interactions (PPI) with 14-3-3.  This protein is a promiscuous binder of other proteins 
with a variety of key functions such as the regulation of proapoptotic proteins (e.g. FOXO, BAD), 
suppression of tumor growth, and sensitizing cells to other drugs.  The promiscuous binding is the 
result of PPIs being shallow binding sites which accept many proteins and modify their activity. 
Compounds which inhibit 14-3-3 include peptides which induce cellular apoptosis.  As a result, 
this interaction has been identified as a potential drug target for future cancer therapeutics, 
however the 7 isoforms are not perfectly redundant adding additional selectivity development as 
an eventual direction. 
The Borch lab has a long standing interest in phosphoramidate prodrugs, here incorporated into 
peptidomimetics, to improve the cellular permeability of charged phosphate compounds.  The 
previous work by Kim et al utilized these prodrugs to develop a modified version of the 
peptidomimetic produced by Shao Q. Yao.2  The original compound (1) had an IC50 of 2.6±0.4 
µM with molecular interactions, while the prodrug analogue (2), which included the 
difluoromethylene phosphonate analogue of the phosphate, had an IC50 near 5 µM in cells.  The 
exact results were unable to be determined as they resulted in cytotoxicity presumably from 14-3-
3 activation.1 
The peptidomimetics designed herein were modeled in comparison with the compounds produced 
by Kim et al.  In this process two prospective binding modes were identified.  One involved a 
linear binding method while another has a bent orientation.  The compounds previously produced 
x 
 
bind in a bent method while those found in the linear method more closely resembled the 
orientation of several peptides designated consensus sequences.  Unsurprisingly those which 
more closely resemble the crystallized consensus sequences produced higher G-scores.  The goal 
of this work was then to produce these compounds for initial confirmation of increased activity 
by these trial runs. 
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Traditional drug discovery has focused on membrane-bound receptors, such that 50% of drugs 
target (class I GPCRs, nuclear receptors, ligand-gated ion channels and voltage-gated ion 
channels) what has been estimated to be 22% of the genetic code.3  Membrane-bound receptors 
serve as the entry to signal transduction, however, these signaling pathways rely on protein-
protein interactions (PPI).  Cellular cross talk between signal transduction pathways may limit the 
effectiveness of targeting membrane bound receptors in order to produce desired downstream 
results.  Additionally, regulatory proteins, which also act via PPI, modulate these pathways in a 
dynamic manner.3 
14-3-3 acts as an allosteric regulatory protein which is approximately 30 kDa and is highly 
conserved (e.g. Saccharomyces cerevisiae has 70% amino acid homology with the human 
protein).4,5  The protein is formed by nine antiparallel α-helices.6  There are seven isoforms (i.e. β, 
ε, η, γ, θ/τ, ζ, and σ) which are all ubiquitously expressed in eukaryotic cells.4,7-9  These form 
homo or heterodimers which act primarily on phosphoserine or phosphothreonine binding sites.10-
12  Among the isoforms, upwards of 200 binding partners have been identified (e.g. lipin-1 in 
adipocytes, BAD, Skp2, Raf, Bcr, and plant nitrate reductase).13 
The nine α-helices of the 14-3-3 protein form an amphipathic groove, where helices three and 
five form a strong polar region on one side, and helices seven and nine form a nonpolar region on 
the other (Shown in Figure 1).13  The amino acids in these four helices are among the most 
conserved region of the protein indicating it may be the primary binding pocket of the 
protein.6,11,14,15  The conserved nature of these amino acids is consistent with the idea that a high 
redundancy of binding occurs among isoforms.  14-3-3 binds to a common consensus sequence to 
bind the many other proteins with which it interacts. Specifically, RSX(pS/pT)XP and 
RX_X(pS/pT)XP (where X is any amino acid), referred to as mode I and II respectively, were 
determined with Ras-1 and other 
 
2 
phosphoprotein interactions.16  The location between the polar and hydrophobic regions of the 
protein  binds these consensus sequences and is referred to as the canonical binding location.  
Additional sequences have been identified, including the QSYpTV-COOH consensus sequence, 
referred to as mode III, which binds outside the major amphipathic groove but includes several of 
the same amino acids.  Mode III binding occurs near the C-terminus of the protein, which occurs 
between the more hydrophobic helices 7 and 9.15,17  The N-terminus is involved in dimer 
formation.  The amino acids of this region are also conserved allowing for the formation of 
heterodimers.14,16 Both dimers can bind simultaneously allowing 14-3-3 to serve as a scaffolding 




Monomer of 14-3-3 structure bound to mode 1 consensus sequence  











14-3-3 was first identified in the brain in a high concentration and named for the fraction upon 
which it was isolated with chromatography techniques.  This identification occurred in 1967.  The 
protein was acidic in nature.  Since this observation, three major activities were identified that 
utilized 14-3-3; however, it has no enzymatic activity of its own.  The major activities thus far 
include: adapter   protein18-20 which bring proteins in proximity, altering enzymatic activity by 
allosteric modification21-23 and cellular localization (notably in ablation of nuclear targeting 
signals)24-29, and vesicle transport.30-32 
The adapter protein function has been studied most extensively with Raf-1.18  There is a crystal 
structure of 14-3-3 bound to I kappa B alpha (nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha) as well as p53.26  The Raf-1 binding intrinsically links the 
protein to the MAPK (mitogen activating protein kinase) activity and pathway.  Adapter activity 
is involved in BCL, PKC, and A20.  Adapter activity has been limited to these observations.  The 
activity takes advantage of the dimer of 14-3-3 proteins where phosphorylated Raf-1 protein 
binds one monomer and the alternative protein is bound by the remaining monomer bringing the 
two within proximity. 
Further insight into the proposed protein binding will help to explain the remaining areas of 14-3-
3 activity.  The dimers form a “W”-like structure, where each dimer forms a binding groove.  The 
N-terminus also forms a floor in these dimers.6,33,  The initial binding event may be called the 
“gatekeeper” which is targeted by phosphoserine/phosphothreonine residues.22 This binding 
greatly increases the possibility of a secondary binding event which stabilizes the binding event 
and has been called the “enhancer” binding event. 
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In the allosteric modification binding event, this occurs due to the protein not fitting in a perfect 
manner.  The binding occurs like an irregular puzzle piece which does not fit perfectly.  This 
results in a bending of the native protein in order to fit the conformation of the 14-3-3 protein.  
This protein bending results in a change in activity.  This is similar to the events which may occur 
by a phosphorylation.  The modification there may alter the conformation and the activity of 
proteins.22 One such example occurs in melatonin synthesis.  Diphosphorylation of 
arylalkylamine  N-acetyltransferase (AANAT) leads to an increase in binding activity of the 
substrate (arylalkylamine).23,35  It has been hypothesized that 14-3-3 binding tightens otherwise 
floppy loops of proteins such as with nitrate reductase and tyrosine/tryptophan 
hydroxylases.21,35,36 
Transport throughout the cell is associated with 14-3-3.  Nucleocyctoplasmic shuttling is one 
process which is modified by the dual binding.  It is hypothesized that the binding partner is 
wrapped around the 14-3-3 protein in order to mask the nuclear signaling of the binding partner.26  
In this manner, proteins targeting to the nucleus have this signal hidden such that these proteins 
are brought into the cytoplasm or limited from nuclear access.  Proteins associated with PKB/Akt 
are one such targeting protein.  bZIP, RSG, CDC25C, FOXO, glucocorticoid receptor and co-
repressor RIP140, p27/kip1, HAT1, acetyltransferase, RbAp48,  HDAC (basic leucine zipper 
domain, repression of shoot group, cell division cycle 25c, forkhead box, nuclear receptor-
intreacting protein 1, cyclin-dependent kinase inhibitor 1B, histone acetyltransferase 1, 
retinoblastoma-binding associated protein 48, histone deacetylases respectively)  are all limited in 
nuclear localization.6,25,27,38-41  Typical movement is associated with transport to the cytoplasm 
from the nucleus; however, telomerase binding transports the protein towards the nucleus.42  
Among the many processes nucleoplasmic shuttling is the most frequent activity described. 
Transportation of proteins from the endoplasmic reticulum to the cell surface is well described. 
The 14-3-3 family of proteins may stimulate this process.  The cellular trafficking from the 
endoplasmic reticulum forms multiple protein complexes towards the final goal of protein 
incorporation into the cellular membrane.  This process is tightly regulated by protein expression, 
but a more dynamic regulatory process limits transmembrane protein forward transport which 
also results in increased protein maturation time.  Interaction of 14-3-3 with potassium channels, 
acetylcholine receptors and immune system complexes alter COPI (coatamer-I coated vesicles) 
binding.  These proteins act to inhibit COPI binding.  This inhibition is one of the predicted 
methods to limit vesicle escape.  14-3-3 in turn binds and inhibits the protein inhibitors of COPI 
allowing the forward transport and transmembrane protein incorporation.29-32 
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While the nuclear signaling may have the largest representation of protein interactions, these 
activities as well as 14-3-3’s biological importance may also be misleading.  The identification of 
activities is largely based on yeast two-hybrid assays where one identifies interactions by proteins 
of existing interest.  Other methods have been utilized to understand 14-3-3 interactions with 
limited value.  Sepharose chromatography has been used to interact with 14-3-3 and pull out 
protein and multi-protein   complexes.13,43,44  Likewise tagged 14-3-3 has been used for extraction 
of proteins of interaction. 
Collectively these methods have allowed another method to identify 14-3-3’s interactions by 
relevant biological processes.  However, the bias of yeast two hybrid interactions has led to a 
higher than average level of interactions with oncogenic pathways as well as plant 
bioengineering.45  The biological processes have included intracellular signaling, trafficking, actin 
dynamics,13 metabolism, ion channel control, cellular processes melatonin biosynthesis, primary 
metabolism, cell cycle control, anti-apoptotic pathways, signaling to cellular proliferation. 
Taken in full these are common processes involved in a wide variety of human disease states.  
One of the most common activities involves the combinations of cell cycle control, anti-apoptotic 
pathways, signaling to cellular proliferation which are the key processes in tumor development.  
The regulatory nature of 14-3-3 in tumor progression through several protein interactions has 
been investigated and a short summary of representative actions should be useful to understand 
14-3-3’s involvement. 
One of the most consistent 14-3-3 interactions in these cellular responses comes from Akt/PKB.  
Many proteins activate this system including insulin, growth factors, GPCR (g-protein coupled 
receptors), integrin, and NGF (nerve growth factor) to name a few.46-48  Downstream of this 
cardiac PFK-2 (phosphofructokinase)49 PDE3 (phosphodiesterase enzyme 3),38 YAP65 (yes-
associated protein 65),39,40 FOXO,50-62 p27, and PRAS39 (proline-rich Akt),53 are all involved in 
signals for proliferation or anti-apoptotic signaling.  For each downstream signal, PKB 
phosphorylates the protein which is followed by 14-3-3 binding.  14-3-3’s role in the downstream 
effects of PKB activities beyond this binding event is still not fully understood, however it is 
clear PKB is involved in cell cycle regulation, proliferation and apoptosis. 
The role of 14-3-3 in p53 regulation is another important interaction.  p53 is a tumor suppressor 
that responds to cellular stress.  In the normal activation of p53, it is enhanced and stabilized by a 
variety of modifications.  When a cell is irradiated, a serine residue becomes dephosphorylated 
leading to 14-3-3 binding.  While the p53 with a dephosphorylated serine retained much of the 
cellular activity, it did not provide G-phase cell cycle arrest.  While many of the isoforms have 
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long been assumed to maintain redundancy, 14-3-3σ seems to hold an alternative function with 
regard to p53.54  Upon nuclear localization, 14-3-3σ becomes expressed leading to cell cycle 
arrest by removing CDK1–cyclin B1 from the nucleus.28 
These comments provide a limited view of the anti-apoptotic, cell cycle control/proliferation 
activities of 14-3-3 due to its large number of interactions.  Since its presence limits apoptotic 
activity, a lack of 14-3-3 protein reasonably would have deleterious effects as well.  As 
previously mentioned, 14-3-3 exists in high concentrations within the brain.  Cell death is a 
hallmark in many neurodegenerative diseases. 
Another common observation in Alzheimer’s and Parkinson’s diseases is protein aggregates 
(neurofibrillary tangles and Lewy bodies respectively).  The subunits of these protein aggregates 
are the focus of plenty of research.  Tau protein, which is involved in neurofibrillary tangles, 
becomes hyperphosphorylated and 14-3-3 facilitates GSK3β activity by bringing it into proximity 
and altering its conformation for phosphorylation.55,56  α-Synuclein and 14-3-3 also share an 
interaction, however, 14-3-3 binding results in a loss of its natural functions.57 As a result, the 
anti-apoptotic activity is lost leading to a dysregulation and a potential cause of cellular death. 
Additional neurodegenerative diseases imply a connection with 14-3-3 proteins including Miller-
Dieker syndrome (MDS),58,59 Creutzfeldt-Jakob disease (CJD)60 and Spinocerebellar ataxia type 1 
(SCA1)61,62.  MDS is caused by the loss of the ε isoform.  CJD has no known interactive function, 
but elevated 14-3-3 proteins have been found in cerebral spinal fluid of patients.  In SCA1, 14-3-3 
limits the degradation of toxic byproducts. 
Recent research would suggest the redundancy of the proteins is not as extensive as previously 
reported.  The sigma isoform has been shown to be among the most important to the cellular 

























































































Molecular inhibitors and molecular stabilizers of 14-3-3 
 
As previously mentioned, the number of interactions with 14-3-3 is in the hundreds and there are 
seven isoforms.  Ideally, targeting specific interactions may be developed between specific 
isoforms or between specific protein complexes.  However, for the most part, chemical 
modification of these interactions is relatively unexplored despite the potential clinical benefit 
from the biological disruptions identified.  In theory, the many interactions of each could be 
stabilized or inhibited.  There have been varieties of both described to date.  The specificity of 
these compounds has in some cases existed between particular PPI but has been limited with 
regards to isoforms. 
Stabilization compounds in general are not a frequently used strategy of drug development as the 
process of stabilizing multi-protein complexes is not as well understood.  Those that do exist 
originate from natural products, such as the TASK3:14-3-3 interaction, and tend to be very 
potent.15  In fact, the identification of natural products that encourage stabilization often lead to 
the identification of novel inhibitors based on the core structure. 
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Several natural products that have stabilized 14-3-3 have been identified.  Fusicoccin A stabilizes 
the PPI between 14-3-3 and a plasma membrane ATPase.51  This makes contact with both 
components to stabilize the compound.63-65 
Cotylenin A is a natural product produced by a fungus.  In combination with interferon-α, 
anticancer activity has been observed.66  There has been no total synthesis of this natural product 
to date, but semi-synthetic methods have allowed for modifications to the structure which indicate 
the core is the most important portion for this activity.  These semi-synthetic methods have 
determined several key enzymes in the production of this core.67-69  This has been hypothesized to 
allow peripheral structural modification within the synthesis.70,71  A high throughput screen did 
elucidate novel stabilizers of the 14-3-3 PPI with the plasma membrane H+ATPase PMA2.72 
Mizoribine is a natural product approved as a drug in Japan.  It has been designed as an 
immunosuppressant that is used for the treatment of several disorders.  It has been described as a 
14-3-3 stabilizer though the direct interaction is not understood.73-75 
Likewise several inhibitors of 14-3-3 interactions have been discovered.  The first was a 20 amino 
acid peptide produced by a phage (PHCVPRDLSWLDLEANMCLP).15,76,  A molecule of this 
size is limited in its ability to penetrate cells even with no phosphorylation.  Similar peptides have 
shown the ability to increase apoptosis and sensitivity to cis-platin in protein assays.77,78 
Several non-peptide inhibitors have been developed as well.  The following is not intended to be 
comprehensive, but a list of compounds that demonstrate isoform specificity, protein disruption 
specificity, and one unique compound are briefly covered.  Lacosamide has been used for some 
time as an anti-epileptic compound.79,   Recently it was identified as a 14-3-3ζ inhibitor.  14-3-
3/c-Abl has been targeted with classical medicinal chemistry structure based drug design 
techniques.  Notably, an irreversible covalent binder has been identified among a library of 
compounds named FOBISIN101 
(FOurteen-three-three BInding Small molecule INhibitor) which also was used to develop a 
derivative with similar activity.80,81  
Peptidomimetics have increased the utility of peptide-based molecules by decreasing the size of 
the compound.  One of the more encompassing strategies was a phosphoserine centered 
“quatramer” derived from the RFRpSYPP 14-3-3 binding sequence by microarray analysis.2  
Even these do not have complete access to the cell as the phosphoserine within the body is in a 
charged state.  In order to resolve this issue, a prodrug strategy used in several phosphoric acids 
has been utilized in the Borch lab.  Previously, this has been used to improve one of the 
compounds developed with the microarray analysis. 
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While many prodrugs were examined, 4-chloro-N-methylbutan-1-amine and (5-nitrofuran-2-
yl)methanol were selected.  Once the compound enters the cell, the (5-nitrofuran-2-yl)methanol 
undergoes enzymatic reduction.  An electron transfer occurs ultimately resulting in its release.  
The excess electron density causes the phosphoramide to cyclize and hydrolyze.  This now frees 
the phosphoric acid for binding.  The enzymatic reduction and subsequent cyclization leading to 































Prodrugs degradation after cellular entry 
 
An additional modification involves the replacement of a phosphate to a non-hydrolyzable 
difluoromethylenephosphonate.  This is an electrically equivalent modification which is inhibited 






























Previous work in the Borch laboratory utilized prodrug activation of the peptidomimetic work of 
Yao.  The purpose of this work was to establish activity within cells by increasing cellular 
permeability.  The Yao compound was identified by small molecule microarray.  The array 
worked on a fragment-based approach towards each side of the test peptide RFRpSYPP while 
validating each fragment by its ability to induce apoptosis.  The current work seeks to utilize 
modeling with the Schrödinger package to develop a compound which inhibits 14-3-3 with a 
higher potency.  The Yao peptidomimetic had an IC50 value of 2.6±0.4 µM in a competitive 
fluorescent polarization assay using a known peptide inhibitor.  Furthermore, they showed 
inhibition of Raf-1 and p53 binding with pull down assays, which confirmed the mechanism of 
action involved inhibition of 14-3-3 binding in the case of these proteins.  The cell-permeable 
prodrug had activity (utilizing a FOXO3a luciferase assay) consistent with this compound; 
however cell toxicity increased at higher concentrations and is assumed to be from 14-3-3 
inactivation. As no crystal structure exists, questions remain regarding the binding mode of the 
compound.  The Yao lab utilized a molecular docking study with Autodock Vina that showed a 
similarity to the native ligand.  Attempts to mimic this study using Glide were done and produced 
a similar result.  However with only a modest expansion of the binding pocket (from 
18Åx18Åx20Å to 20Åx20Åx20Å) another higher scored binding mode was observed.  These will 
be respectively referred to as the linear and bent modes as displayed in Figure 3.  For Compound 






Binding pocket size created linear (magenta) and bent (cyan) modes of Compound 1.  
 
In order to make effective peptidomimetics, the first approach would refer to the interaction with 
the consensus sequences and the known information of the structure.  As a reminder, mode I is 
R(X/S)XpSXP while mode II is R XφXpSXP, where x is any amino acid, while φ is specifically a 
hydrophobic amino acid.  The discriminating point between these two modes is the position of the 
arginine relative to the phosphoserine.  Additionally, while mode I does not require the -2 
position to be a serine it frequently is.  This serine acts in a regulatory manner where its 
phosphorylation reduces the ability of peptides to bind.82 
When one looks at the representative consensus peptide (cyan in Figure 4), which had its bound 
crystal structure determined by x-ray crystallography, it becomes clear why the phosphorylation 
of this serine becomes important.83  Glutamic acid 182 and tryptophan 230 (yellow in Figure 4) 
create a crease which accepts the serine hydroxyl side chain to form a H-bond.  If this -2 serine 
were phosphorylated, then the serine would be pushed away from this crease, both from the Van 
der Waal and electrostatics, and away from the peptide binding groove.  Likewise any molecule 
or peptide should account for these interactions.  The three salt bridges and a possible H-bond 
donor (formed by ARG 56, LYS 49, ARG129, and TYR130) are used to form the primary 
phosphoserine/phosphothreonine binding site.  In peptides, proline has been shown as an 
advantageous, but non-critical selection at the +2 position of the consensus sequence.26  In this 
crystal structure, this hydrophobic residue is just barely entering a pocket (Formed by SER45, 
PHE 119, LYS 122, MET123, ASP 126, and TYR126-Magenta)  Both the polar residues (bolded) 
are at the top of the pocket  forming the  edge of the typically polar helices to this side.  However 
there is a gap into a more nonpolar core of these helices which can develop hydrophobic 
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interactions.  A peptide would have to be folded specifically to interact with this while a nonpolar 




Consensus sequence mode I binding and major interactions 
 
If one considers the consensus sequences and knowledge of the protein structure together now, 
then we can begin to envision goals for developing new ligands. The phosphoserine becomes 
fixed between one group of arginine residues in the protein.  This offers the greatest point of 
stabilization but it also offers a fixed binding point in which to consider the surrounding 
interactions of peptides and peptidomimetics.  Roughly it should be remembered the binding 
pocket itself is amphoteric with helices three and five creating the polar phosphoserine binding 
pocket and seven and nine are remaining largely nonpolar.  The intuitive goal would be to have 
part of a designed peptidomimetic be polar to interact with the polar helices and the opposite end 
be nonpolar to interact with the helices on the other side of the groove.  This effectively lodges 
the compound in the groove.  However, considering the consensus peptide interactions the 
opposite effect is seen (Figure 4).  The polar serine end finds the polar exception (GLU 182) in 
 
13 
the otherwise nonpolar helices, while the nonpolar side finds the hydrophobic pocket in the 
otherwise polar helices (from here forward referred to as “like binds unlike mode” as opposed to 
“like binds like mode”).  These unusual regions of interest may be providing more fixed locations 
where enthalpy gains don’t require the entropic losses.   The shallow elongated nonpolar section 
of the groove would allow a higher amount of water contacts and a lower benefit of desolvation.  
The ability of the side chains to slide into enthalpically favorable locations along the groove will 
also increase the conformational energy loss of side chains or those parts which act like them.  By 
reducing the options for side chain interactions this can act as an artificial rigidification. 
Comparing this principle (N-terminus is polar while the C-terminus is nonpolar) within the 
framework of consensus sequence to the existing peptidomimetic 1 may provide some 
information about where to construct future molecular development.  Toward the C-terminus 
tyramine is used.  Tyramine is effectively a mimetic of tyrosine, which is a non-polar amino acid 
(this can be illustrated by looking at the log P of the side-chain (plus a carbon for the bridge 
point) as a positive value).  On the other end of the existing peptidomimetics is 4-azidobenzoic 
acid (Figure 3) which also has a highly positive log P.  Despite having a higher polar surface 
area, it is significantly more hydrophobic as a molecule.  Compare this side chain to the side-
chain of serine which would ideally bind in the same location from the peptidomimetic and it is a 
negative log P.  This is unsurprising as it is a polar amino acid.  The situation arises that both 
sides of this current peptidomimetic have nonpolar side-chains.  This makes the calculated bent 
mode less surprising as both hydrophobic sides cannot fit into the hydrophobic pocket observed 
in helices three and five. 
The apparent goal would be to design something with a more hydrophilic side chain that can act 
interact with the polar protrusion (GLU182) of the seven and nine helices (as previously shown in 
Figure 1) producing the linear binding mode. The modeling started with the belief that a more 
linear binding mode which mimicked the consensus sequences would produce a higher G-score 
and activity of inhibition for in vitro tests.  In several compounds with similar C log P values, one 
observes the same bent binding method as the observed compound.  In the two notable cases of 
an indoline-4-carboxylic acid and  
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isoquinoline-5-carboxylic acid modification at the -2 position, a linear binding mode with a high 
g-score is calculated.  From these compounds, it seemed a similar distance charge distribution 
could be produced by a quinoline-5-carboxylic acid which made it a logical additional 
modification.  Likewise both of these compounds have lower clog P values.  Further reasoning 
for this can be drawn when indoline-4-carboxylic acid was N-methylated/ethylated.  The binding 
mode reverts, the C log P increases and the G-score decreases. 
Table 1 
Analogues synthesized based on binding modes, and G-score with their C Log P 
Compound "side-chain" at -2 Position C Log P1 TPSA G-Score Binding Mode 
Tyrosine  2.503 20.23 N/A N/A 
      
4-Azidobenzene 2.584 48.76 -8.595 Linear 
4-Azidobenzene 2.584 48.76 -10.344 Bent 
Indole  2.132 12.03 -9.238 Bent 
Isoquinoline 1.819 12.36 -11.348 Linear 
Indoline  1.776 12.03 -13.000 Linear 
Quinoline 2.029 12.36 -9.668 Bent 
      
N-acetyl-indoline 1.362 20.31 -8.528 Linear reversed mode 
N-formyl-indole 1.457 20.31 -11.664 Linear 
 
First thing to note is many molecules can be made with lower C log P values.  Five were tested in 
the original work that identified the 4-azidobenzoic carboxylic acid and displayed insignificant 
activity.2  (These five were as follows- N191 (picolinic acid), N236 (3-nitrobenzoic acid), N147 
(3-cyanobenzoic acid), N126 (3-cyanobenzoic acid), N179 (thiophene-2-carboxylic acid)), as 
though the samples are reduced by perceived substitution patterns described below.) These are 
smaller compounds that do not make the H-bond to GLU182 described below that would 
contribute to lower binding values, however, as described with the quinoline below this is not 
sufficient to ablate activity as fully as seen in their assay.  One additional reason for this may be 
elicited by the N-acetyl modification of the indoline.  Of those presented here, it produces a linear 
mode as well, but it is reversed in the like binds like method originally hypothesized (Figure 5).  
It is also given a lower g-score, which further implies the disadvantage of a like binds like  
1. The C log P given here is for the side chains at the -2 N-terminus 
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mode.  In some cases this also presented with a bent mode that directed the other direction from 
the normally observed bent mode.  This result would suggest there is an acceptable window (2-
1.3) for the utilization of C log P of side chains (Table 1).  While a window may be descriptive, 
C log P values near the boundary values should not be assumed to form one binding mode over 
another as the exact cut off is unknown and there is unlikely to be a sharp cut-off as well.  As 





The reverse linear phase binding mode of N-acetyl indoline with low C log P 
 
It would be inaccurate to suggest the log P value of side chains is the only factor in binding.  In 
the case of the -2 N-terminus the distance between the amide which connects to the rest of the 
molecule and the H-bond has a range of acceptable lengths of three π bond length separation 
while four does not form this H-bond as in the case of the isoquinoline (Figure 6).  Based on G-
score differences this is approximately the same contribution afforded to the 4-azidobenzene 
substituted analogue relative to other bent mode molecules (Between 1-1.5 g-score values).  This, 
regardless of log p, can in part explain the lack of better binding among naphthalenes with amino 
or hydroxyl substituents. 
When examining the predicted binding mode of the indoline-4-carboxylic acid and isoquinoline-
5-carboxylic acid, the binding mode also indicates a ring which is in close proximity thereby 
limiting substitution patterns to a position ortho and meta (to the same side) to a given initial 
substituent.  In the case of the indoline, where the ring is proximal to the backbone of the 
structure is in close proximity, the carboxylic acid serves as the initial substituent and can only be 
16 
further substituted at the position ortho and meta to it.  In the case of an isoquinoline, the ring 
system rotates but the required substitution pattern is similar.  The distal ring is closer to the 
protein and reduces its available substitution pattern.  Its modified position limits the ability of the 
compound to form H-bonds to GLU182.  It is proposed that the extra distance between the amide 
and the H-bond doesn’t allow it to position where the H-bond can form which produces the 
rotated position.  This is best suited for a rigid structure that locks the H-bond into place with an 
ideal distance between amide and H-bond.  In the isoquinoline, a linear binding compound, the 





Indoline and isoquinoline binding modes with H-bond to GLU182 
 
As for the initial assumption, a linear normal mode compound on average afforded approximately 
a 2 G-score point advantage here.  An example is the comparison of quinoline and isoquinoline 
where the H-bond to the protruding GLU residue is not present.  One large contribution will be 
the interaction into the hydrophobic pocket along helices three and five; however it is not entirely 
likely this is the source of the entire contribution as the complete binding mode changes including 






Quinoline and isoquinoline binding modes to compare binding the hydrophobic pocket 
Extensive modeling was not attempted for the C-terminus of these potential inhibitors.  Most 
efforts attempted to produce additional H-bonds within the otherwise hydrophobic pocket.  
Chloro and methyl substitutions were attempted but also resulted in decreased activity though the 
localization of these ortho to the phenolic hydroxyl group may play some role. 
Additionally, N-acyl and N-formyl indolines were synthesized.  With the initial success of the 
indoline binding, minor modifications were attempted in order to increase the lipophilicity of the 
-2 peptidomemetic while seeing if GLU182 would maintain its H-bonding character.  As 
discussed, it becomes more heavily lipophilic a reverse binding mode is observed in the case of 
the N-acetyl indoline.  However, the N-formyl compound resulted in the normal linear binding 
without H-bonds.  





































































































A complete illustration of final analogues to be synthesized for 14-3-3 inhibition studies 
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The synthesis of the compounds such as 3-8 proposed from the modeling is detailed below.  The 
bulk of the synthesis followed those previously designed to make the compound 2 which utilized 
the creation of the chiral aziridine 13 from prochiral serinol 9.82 
The synthesis of the aforementioned aziridine is given in Scheme 2.  First serinol is protected on 
the more nucleophilic nitrogen with a tosyl group.  This N-tosyl serinol (10) is prochiral and is 
acetylated with porcine pancreatic lipase (PPL), to selectively form the chiral O-acyl compound 
(11).  The remaining hydroxyl group is then protected as the tert-butyl dimethylsilyl ether (12).  
Without further purification the O-acyl group is cleaved.  This then allows an intramolecular 
















a) b) c) d)
a)  TsCl (1 eq), NEt3 (1.1 eq) DCM, Acetone
b) Vinyl Acetate, PPL
c) TBSCl (1 eq) Imidazole (1.7 eq) DCM, K2CO3 (1 Eq) MeOH
d) PPh3 (1.5 eq), DIAD (1.4 eq), THF 0oC
9 10 11 12 13
 
Scheme 2 
Synthesis of chiral aziridine. 
Next, diethyl difluoromethylphosphonate enolate is produced with an excess of freshly prepared 
LDA made from freshly distilled n-butyl lithium (Scheme 3).  A useful observation in the 
formation of product is that the enolate becomes red, while addition of the aziridine forms a 
brown color until quenching with sat. NH4Cl.  The enolate is used to 
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open the aziridine at the unsubstituted carbon while forming a new bond.  The resulting 
phosphonate compound (14) is converted to the BOC-protected compound 15 by reaction with 
BOC anhydride and subsequent reductive elimination of the tosyl group.  The product (15) then 
has the silyl ether and carbamate cleaved in one step to afford the alkanolamine phosphonate 
which, without purification, is converted to the Fmoc-protected compound 16  by treatment with 
fluorenylmethyloxycarbonyl chloride.  The hydroxyl group is then protected as the acyl ester 




















a) LDA (3 eq), diethyl (difluoromethyl)phosphonate (3 eq) HMPA 65%
b) Boc2O (3.5 eq), DMAP (1.1 eq), THF ii) Mg (10 eq), MeOH 82% 
c) MeOH (s) HCl (conc.) 1 hr rt, ii) DIPEA (2.5 eq), FmocCl (1.05 eq), DCM 90%




























Synthesis of protected phosphonoserine analog 17 
Scheme 4 shows the reactions for the synthesis of the relevant prodrugs.  Aldehyde (18) is 
reduced with sodium borohydride to (19) the corresponding alcohol (from here out in schemes as 
P1).  For the other prodrug substituent, excess methylamine is reacted with 4-chlorobutanol (20) 
to form the secondary amine (21).  The compound is then acidified with HCl and reacted with 





















a) NaBH4 (1.05 eq), MeOH 0oC
b) MeOH, NH2CH3
c) SOCl2, THF  
Scheme 4 
Formation of prodrugs components 
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Compound 17 is reacted with trimethylsilyl iodide under strictly anhydrous conditions to form the 
silyl phosphonate (23), which is converted directly to the phosphonic dichloride (24) by reaction 
with oxalyl chloride.  Then 24 is reacted sequentially with the amine chloride 22, which produces 
the desired phosphoramide chloride (25) and with the alkoxide of (19) to form 26.  The acetate 
(26) is then cleaved and the resulting alcohol is converted under Jones oxidation conditions to 





























a) i) TMSI (3 eq) DCM 20hr, P31=43, hydrolysis P31=15, SM P31= 5
b) C2O2Cl2, HCCl3, DMF (cat) 
c) HCl amine HCCl3, DIPEA:HCCl3 2:1 -78oC--> -25oC Yield ~49%
d) Nitrofurfuryl methanol (1.5 eq), LHMDS (1.5 eq) THF, ii) Phosphoryl chloride, THF -78oC 18 hr          
Yield 50%



































Synthesis of phosphonoserine 27 
This carboxylic acid is then coupled to tyramine to form the amide (28).  The Fmoc is then 
























a) PyBOP (1.1 eq), Tyramine (1.1 eq) DIPEA (2.2 eq) 0oC--> 10min RT 30 min DCM (10 
mL/0.5mmol) 65%, 79%
b) DBU (1.4 eq), DCM ( 1ml/mmol) 0oC, 22 hr 55%  
Scheme 6 
Synthesis of phosphonoseryltyramine 28 
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The modeling required new substituents at the N-terminus of this serine core.  This begins by the 
examination of the four major cores at the -2 position.  These are substituted indole, indoline, 
quinoline and isoquinoline cores.  The isoquinoline (31) and quinoline (32) compounds are 
commercially available so they are directly coupled to ethyl glycinate (33, and 34, respectively).  

































a) CrO3, H2SO4/H20 (60%), Acetone 50%
a) DIC (2.5 eq) HOBt (2 eq) ethyl glycine hydrochloride, (1 eq), THF rt 30 min DIPEA (1.1) 18 hr













Formation of glycine amides of 5-carboxyl substituted iso/quinoline 
The indole and indoline compounds require some modifications.  Both are formed from 1H-
indole-4-carboxylic acid (37).  For the synthesis of the indoline,82 the indole methyl ester is 
formed (38) and reduced via catalytic hydrogenation. In theory, esterification should be 
unnecessary, although it effectively doubled the yields of the reduction product in my hands.  
Finally, the indole and indoline nitrogens are Boc protected to give the indole (40) and indolines 






















a) MeOH, H2SO4 (1eq) reflux 8 hours 98%
b) H2, Pd/C (10%), H2ClO4, AcOH 68%
c) Boc2O (1.1 eq), DMAP (cat.), DIPEA (1 eq) THF 99%
d) Boc2O (2 eq), DMAP (cat.), NEt3 (2 eq), THF 49%
 
Scheme 8 
Boc protected indole/indolines as precursors to final peptidomimetics. 
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The secondary amine acts as an H-bond acceptor.  The first attempt to examine this involved 
converting the amine into an N-acetyl analog.  This furthered the initial hypothesis of a more 
lipophilic end binding better and potentially created an H-bond acceptor.  However, molecular 
modeling suggested a reversed binding mode.  There were no observable H-bonds in this 
compound, suggesting the lipophilicity was the primary change in this binding mode.  This was 
still a valuable analogue to create in order to test if the binding mode correlates to the binding.  In 
the goal, of still improving binding with while changing the system to an H-bond donor, the N-
formyl analogue was made and reduced the lipophilicity while maintaining the binding mode.  As 
predicted, the H-bond contributes to the G-score.  The acetyl group is added by acetic anhydride 
















a) Ac2O (1.1 eq), DMAP (cat.), DIPEA (1 eq) THF 99%







Acetyl and formyl analogues synthesis from intermediate 39 
The ester group of each indole/indoline (40, 42, 43) is hydrolyzed to give the corresponding acid 
(44a-c).  The indolines (41 and 44a-c) are then coupled to ethyl glycinate.  The ester groups of 
these acylglycinate (45a-d) are hydrolyzed to give the corresponding acids 46a-d.  The general 





















40, 42, 43 44 a-c, 41 45 a-d 46 a-d
a) MeOH/DCM (2:1), KOH (2M in MeOH)
b) Ethyl glycine (2 eq), DCI (2 eq), HOBt (2 eq), 30 min, THF, 44 a-c, 41, DIPEA (2.2 eq)




















Synthesis of indole (d) and indoline (a-c) glycine amide precursors 
The six carboxylic acids from the N-substituted glycines (35, 36, and 46 a-d) are then coupled to 
the serine analogue to afford the four final products 3, 4, 7 and 8.  The boc protected indole and 
































a) PyBop (2 eq), DIPEA (2 eq), THF 18 hr






46 a-d, 35, 36 29 48 a-h
 
Scheme 11 








The goal of this thesis was the design and synthesis of novel compounds for the inhibition of 14-
3-3 protein-protein interactions.  These compounds sought an improvement in activity over the 
existing difluoromethylphosphoserine prodrug previously synthesized in our lab.  A correlation 
between the G-scores and binding data should first be established as a preliminary validation of 
the hypothesis.  In previous work, a cellular assay was developed which can produce inhibitory 
data values.  As a result, four of the compounds were selected for synthesis.  One of these, the 
indoline, had a significantly improved G-score (13 v 10.344), while the remaining three have G-
scores similar to the previously assayed compound. 
In order to assess the validity of this model biological testing must be run on these compounds.  A 
growth inhibition assay was devised for the previously synthesized difluorophosphoserine 
peptidomimetic.  This would serve as a preliminary screen for the synthesized compounds.  There 
are potential drawbacks in this screening method.  It is not a direct demonstration that the 
compounds are interacting with the 14-3-3.  
The significant difference in this predicted affinity comes from a moderate increase in the size of 
the assayed binding pocket.  This then elicits two binding modes.  One thing unexplored here is 
extending the backbone of the existing compound 2 which may allow the azidobenzene to remain 
where it currently binds and the tyramine to reach the hydrophobic pocket.  This would put the 
relevant functional group at the -3 position rather than the -2.  While preliminary attempts to 
modify the tyramine aromatic substitution were made, additional exploration of +1 











The modeling was performed using the Maestro suite by Schrödinger.  The 14-3-3ϭ protein 
bound to the mode I consensus sequence was downloaded from the Protein Data Bank.  Centered 
at the phosphoserine binding site a 20Ǻx20Ǻx20Ǻ binding site is created.  Hydrogen bonds were 
optimized and the protein was minimized (RMSD=0.3Ǻ) with the OPLS 2005 force field.  
Compounds were constructed in ChemDraw, imported  and the ligand was prepared using the 
Epik condition and with amide bonds rotatable. The consensus sequence was then removed from 
the binding site, followed by rebinding this compound for confirmation.  The bonds to the water 
molecules were optimized.  The energy of the protein was minimized.  A docking study is then 
performed betweent he protein and the ligand, which displays the binding mode, any H-bonds, 
and the Glide-score. 
Unless otherwise stated, solvents should be considered to have been dried.  MeOH was dried over 
4 Å molecular sieves.  THF was dried over a solution of benzophenone and sodium.  DCM was 










Procedure- Serinol (1.82 g, 20 mmol) was dissolved in EtOH (60 mL) which had NEt3 ( 3.1 mL, 
22 mmol) added at 0oC.  At this temperature, TsCl (3.8 g, 20 mmol) was then 
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added and brought to room temperature.  This was then allowed to react for 2 h.  The reaction 
was then concentrated and redissolved in acetone (100 mL) to allow the precipitation of NEt3 
hydrochloride.  This was filtered and washed with acetone.  This was purified by flash silica gel 
chromatography to yield N-(1, 3-dihydroxypropan-2-yl)-4-methylbenzenesulfonamide in a 99% 
yield as a white solid (4.56 g, 16.6mmol). 
1
H NMR (300 MHz, CDCl3) δ 7.83 (d, 2H, J=8.4 Hz), 
7.09 (d, 2H, J=8.4 Hz), 6.6 (br-s, 1H), 4.3 (m, 1H, J=12) 3 4.25 (dd, 4H, J=15, 7.5 Hz), 3.30 (br 









Procedure- N-(1,3-Dihydroxypropan-2-yl)-4-methylbenzenesulfonamide (4.56 g, 16.6mmol) 
was dissolved in vinyl acetate (396 mL).  To this porcine pancreatic lipase (PPL) (5.94 g) was 
added and stirred vigorously for 3 h.  The reaction was then filtered through celite and 
concentrated under reduced pressure.  The residue was purified by flash silica chromatography to 
yield 3-hydroxy-2-(4-methylphenylsulfonamido)propyl acetate 91% (4.33 g, 15.10 mmol) 90:10 
ER.  (R)-3-Hydroxy-2-(4-methylphenylsulfonamido)propyl acetate was isolated by 





) δ 7.74 (d, 2H, J=8.4 Hz), 7.25 (d, 2H, J=8.4 Hz), 5.92 (d, 1H, J=7.8 Hz), 4.00 









Procedure- (R)-3-Hydroxy-2-(4-methylphenylsulfonamido)propyl acetate (4.1 g, 14.28 mmol) 
was dissolved in DCM (70 mL)  To this imidazole (1.65 g, 24.28 mmol) was added and the 
reaction was cooled to 0oC.  This mixture then had TBSCl  (2.37 g, 15.71 mmol) added in one 
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portion.  This was reacted for 1 h at room temperature.  This was washed with sat. NH4Cl (25 
mL).  The NH4Cl was backwashed with DCM (2X25 mL).  The combined organic fractions were 
then dried over Na2SO4.  The residue was concentrated and used directly in the next step. 
1
H 
NMR (300 MHz, CDCl
3
) δ 7.74 (d, 2H, J=8.4 Hz), 7.25 (d, 2H, J=8.4 Hz),  5.92 (d, 1H, J=7.8 
Hz), 4.00 (m, 2H), 3.97 (m, 1H), 3.73 (m, 1H), 3.63  (m, 1H), 2.37 (s, 3H), 1.85 (s, 3H), 0.88 (s, 










Procedure:  The (S)-3-((tert-butyldimethylsilyl)oxy)-2-(4-methylphenylsulfonamido)propyl 
acetate residue was dissolved in methanol (70 mL).  To this K2CO3 (1.47 g, 14.28 mmol) was 
added at 0oC.  The reaction proceeded for 1 h.  This was diluted with EtOAc (100 mL) and 
quenched with sat. NH4Cl (20 mL).  The NH4Cl was washed with EtOAc (2X25 mL).  The 
combined organic phases were dried over Na2SO4 and concentrated.  This oil was purified by 
flash silica chromatography to give (S)-N-(1-((tert-butyldimethylsilyl)oxy)-3-hydroxypropan-2-
yl)-4-methylbenzenesulfonamide in 96% (4.92 g, 13.71 mmol) yield over 2 steps as a dark yellow 
oil. 
1
H NMR (300 MHz, CDCl
3
) δ  7.74 (d, 2H, J=8.4 Hz), 7.25 (d, 2H, J=8.4 Hz),  5.92 (d, 1H, 
J=7.8 Hz), 4.19 (m, 2H), 3.97 (m, 1H), 3.73 (m, 1H), 3.63  (m, 1H), 2.37 (s, 3H), 0.88 (s, 9H) -












methylbenzenesulfonamide (1.22 g, 3.39 mmol) was dissolved in THF (20 mL).  To this PPh3 
(1.33 g, 5.09 mmol) was added followed by DIAD (0.933 mL, 4.74 mmol) at 0oC.  The reaction 
was allowed to proceed for 8 h at room temperature and concentrated.  The reaction was 
recrystallized in cold ether:hexane (4:6) and the triphenylphosphine oxide was filtered out.  The 
resulting filtrate was concentrated and purified by silica flash chromatography to yield (S)-2-
(((tert-butyldimethylsilyl)oxy)methyl)-1-tosylaziridine in a quantitative yield (1.15g, 3.39 mmol) 
and as a viscous yellow oil..
 1
H NMR (300 MHz, CDCl
3
) δ  7.74 (d, 2H, J=8.4 Hz), 7.25 (d, 2H, 
J=8.4 Hz), 3.80 (dd, 2H), 2.64 (m, 1H), 2.37 (s, 3H), 2.30 (d, 2H, J=5.7 Hz), 2.23 (d, J=3.9 Hz) , 
















Procedure:  DIPA (0.77 mL, 5.5 mmol) was dissolved in THF (2.5 mL) and HMPA (0.956 mL, 
5.5 mmol) then cooled to 0oC.  To this freshly titrated n-BuLi (3.09 mL) in hexanes (5.5 mmol) 
was added dropwise.  The solution was allowed to react for 30 min and the reaction turned a deep 
yellow color. The solution was then cooled to -78oC. Diethyl (difluoromethyl)phosphonate 
(0.941g, 5 mmol) was dissolved in THF (2.5 mL) and added dropwise.  The reaction procedure at 
this temperature for 45 min and turned a dark red color.  To this (S)-2-(((tert-
butyldimethylsilyl)oxy)methyl)-1-tosylaziridine (0.852 g, 2.5 mmol) in THF (2.5 mL) is added 
dropwise.  The reaction then proceeded for 18 h.  The reaction was quenched with NH4Cl (5 ml) 
at -78oC and allowed to slowly warm to room temperature.  The reaction mixture was diluted 
with EtOAc (3x30 mL) and dried over Na2SO4.  This was then concentrated and purified by flash 
silica chromatography to give (S)-diethyl(4-((tert-butyldimethylsilyl)oxy)-1,1-difluoro-3-(4-
ethylphenylsulfonamido)butyl)phosphonate in a 69% yield (1.82 g, 3.45 mmol) as a pale yellow 
oil.  1H NMR (300 MHz, CDCl3) δ 7.70 (d, 2H J= 8.1 Hz), 7.25 (d, 2H J= 8.1 Hz), 5.21 (d, 1H J= 
7.2 Hz), 4.19 (m, 4H), 3.66 (m, 1H), 3.54 (dd, 1H, J = 10.1, 3.8 Hz), 3.43 (dd, 1H, J = 10.1, 4.3 
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Hz), 2.36 (s, 3H), 2.35-2.28 (m, 2H), 1.30 (t, 6H, J = 6.9), 0.78 (s, 9H), -0.06 (s, 3H), -0.08 (s, 
















ethylphenylsulfonamido)butyl)phosphonate (0.90 g, 1.70 mmol) was dissolved in THF (20 mL).  
Boc2O (1.3 g, 5.95 mmol) was added followed by DMAP (0.260 g, 2.13 mmol) at room 
temperature.  This was allowed to stir for 1 h.  The reaction mixture then had sat. NH4Cl (10 mL) 
added.  This was then extracted with EtOAc (2X30 mL).  The combined organic fractions were 













Procedure:  The proceeding compound was dissolved in MeOH (20 mL).  To this powdered 
magnesium (0.41 g, 17.0 mmol) was added and sonicated for an hour.  The solution was diluted 
with DCM (40 mL) and was slowly quenched with sat. NH4Cl until all metal had dissolved.  This 
was then washed with sat. NaHCO3 (20 mL) and back washed with DCM (3x20 mL).  The 
combined organic fractions were dried over MgSO4 and concentrated.  This was then purified by 
flash silica chromatography to obtain (S)-tert-butyl (1-((tert-butyldimethylsilyl)oxy)-4-
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(diethoxyphosphoryl)-4,4-difluorobutan-2-yl)carbamate in 62% percent yield (0.50 g, 0.807 
mmol) over 2 steps as a clear liquid. 1H NMR (300 MHz, CDCl3) δ 4.84 (br d, 1H, J = 7.0, 4.21 
(qu, 4H, J= 7.1 Hz), 4.01 (br s, 1H), 3.64 (dd, 1H, J= 10.6, 3.0 Hz), 3.58 (dd, 1H, J= 10.0, 4.4 
Hz), 2.27 (m, 2H), 1.38 (s, 9H), 1.32 (t, 6H, J= 7.1 Hz), 0.83 (s, 9H), -0.01 (s, 6H) 31P NMR 
















difluorobutan-2-yl)carbamate (1.0 g, 2.10 mmol) was dissolved in MeOH (20 mL).  This was 
cooled to 0oC and conc. HCl (2 mL)was added.  The solvent was concentrated, and acetonitrile 
(2x40 mL), then toluene (40 mL) was added and co-evaporated.  To this DCM (30 mL) was 
added and cooled to 0oC.  To this DIPEA (0.742 mL, 6.30 mmol) was added followed by FmocCl 
(0.598 g, 2.31 mmol).  This was then slowly brought to room temperature and allowed to react for 
18 h.  The reaction was quenched with sat. NH4Cl (15 mL) and extracted with DCM (2X15 mL).  
This was then dried over Na2SO4 and concentrated.  The mixture was purified by flash silica 
chromatography to yield (S)-(9H-fluoren-9-yl)methyl(4-(diethoxyphosphoryl)-4,4-difluoro-1-
hydroxybutan-2-yl)carbamate  92% (0.92 g 1.93 mmol) as a yellow liquid. 1H NMR (300 MHz, 
CDCl3) δ  7.74 (d, 2H, J = 7.4 Hz), 7.59 (d, 2H, J= 7.4 Hz), 7.39 (t, 2H, J= 7.4 Hz), 7.30 (t, 2H, 
J= 7.4 Hz), 5.55 (br d, 1H, J= 7.4), 4.23 (m, 8H),  3.74 (m, 2H), 2.97 (m, 1H), 2.49-2.36 (m, 2H), 
1.36 (td, 6H, J= 7.0, 2.8 Hz), 31P NMR (CDCl3) δ  18.5 (t, J= 108 Hz), 19F NMR (CDCl3) δ -



















2-yl)carbamate  (0.78 g, 1.49 mmol) was dissolved in DCM (5 mL) and acetic anhydride (1.08 
mL, 3.86 mmol) was added.  To this DIPEA (0.677 mL, 3.86 mmol) and DMAP (cat.) were 
added.  The reaction was quenched with brine (2 mL) and extracted with DCM (2x10 mL).  This 
was then dried over Na2SO4 and concentrated.  Purification was done by flash silica 
chromatography. (S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(diethoxyphosphoryl)-
4,4-difluorobutyl acetate was isolated in 66% (0.52 g, 0.983 mmol) yield as a dark yellow oil. 1H 
NMR (300 MHz, CDCl3) δ  73 (d, 2H, J = 7.4 Hz), 7.57 (d, 2H, J= 7.4 Hz), 7.37 (t, 2H, J = 7.4 
Hz), 7,28 (t, 2H, J= 7.4 Hz), 5.53 (d, 1H, J= 8.2 Hz), 4.37-4.19 (m, 10H), 2.46-2.31 (m, 2H), 2.04 
(s, 3H), 1.38-1.31 (m, 6H) 31P NMR (CDCl3) δ –18.7 (t, J = 106 Hz), 19F NMR (CDCl3) δ -112.4 








Procedure: MeOH (15 mL) was put into a pressure tube.  This was cooled to -78oC and MeNH2 
(50 mL, ~750 mmol) was condensed. 3-chloropropan-1-ol (16.09 g, 150 mmol) was added 
dropwise at this temperature.  The cap was sealed and the reaction was allowed to warm to room 
temperature and heated to 80oC for 16 h.  The reaction vessel was then brought to room 
temperature and slowly unsealed.  The solvent was the concentrated under reduced pressure.  The 
reaction yielded 3-(methylamino)propan-1-ol 55% (8.57 g, 83.1 mmol) as a yellow oil. 1H NMR 





N Cl H Cl  
3-Chloro-N-methylpropan-1-amine hydrochloride 
Procedure: 3-(Methylamino)propan-1-ol  (8.57 g, 83.1 mmol) was dissolved in DCM (25 mL).  
The mixture had HCl (g) bubbled through the solution until pH is 5.  The solution was then 
cooled to 0oC and thionyl chloride (6.2 mL, 85 mmol) was added dropwise with stirring.  The 
solution was allowed to warm to room temperature and then stirred for 4 h.  The reaction mixture 
was then co-evaporated with DCM (25 mL) and recrystallized with EtOAc (50 mL).  This was 
co-evaporated with toluene, and lyophilized prior to use.  3-Chloro-N-methylpropan-1-amine 
hydrochloride was obtained in an 85% yield as a white solid (10.17 g 70.64 mmol). 1H NMR 


















difluorobutyl acetate (0.310 g, 0.571 mmol) was dissolved in DCM (5 mL) and TMSI (0.243 mL, 
1.71 mmol) was added at room temperature and stirred for 20 h.  The reaction was then 
concentrated under reduced pressure and co-evaporated with DCM (3x5 mL).  This was then re-
diluted with DCM (5 mL) and 1 drop of DMSO.  This solution then has oxalyl chloride (0.122 
mL, 1.42 mmol) added dropwise and was stirred for strictly 1 h.  The solution was co-evaporated 
with DCM (3x5 mL) followed by toluene (5 mL).  This crude mixture was re-dissolved in DCM 
(5 mL) and cooled to -78oC.  This was added to a solution of 3-chloro-N-methylpropan-1-amine 
hydrochloride (0.085 g 0.542 mmol) in DCM (5 mL) at -78oC.  This was followed by a dropwise 
addition of DIPEA (0.231 mL, 1.42 mmol).  This was warmed to -25oC and maintained at this 
temperature for 20 h.  To the reaction sat NH4Cl (3 mL) was added.   The reaction was extracted 
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with DCM (3x10 mL) and the combined organics were dried over Na2SO4.  This was 
concentrated and purified by flash silica chromatography to afford (2S)-2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-4-(chloro((4-chlorobutyl)(methyl)amino)phosphoryl)-4,4-
difluorobutyl acetate in a 92% (0.310 g, 0.525 mmol) yield as a pale yellow oil. 1H NMR (300 
MHz, CDCl3) δ 7.75 (d, 2H, J = 7.4 Hz), 7.58 (d, 2H, J= 7.4 Hz), 7.39 (t, 2H, J= 7.4 Hz), 7.30 (t, 
2H, J= 7.4 Hz), 5.36 (m, 1H), 4.29 (m, 6H), 3.54 (m, 2H), 3.23 (m. 2H), 2.81 (d, 3H, J= 12.2 Hz), 
2.46 (m, 2H), 2.07 (s, 3H), 1.76-1.74 (m, 4H) 31P NMR (CDCl3) δ –4.8 (t, J= 110 Hz), 19F NMR 







Procedure: 5-Nitrofuran-2-carbaldehyde (5.8 g, 41.13 mmol) was dissolved in a round bottom 
flask with MeOH (75 mL).  A condenser was attached and NaBH4 (1.64 g 43.12 mmol) was 
added in several portions with stirring.  When all the NaBH4 was added the reaction mixture was 
heated to reflux for 1 h.  The mixture was brought to room temperature and the solvent removed 
under reduced pressure.  The mixture was dissolved in DCM (60 mL) and sat. NH4Cl (10 mL) 
was added and back extracted with DCM (2X30 mL).  The combined organic phases were dried 
over Na2SO4 and concentrated. (5-nitrofuran-2-yl)methanol was isolated in 84% yield as a clear 
oil (4.92 g, 34.41 mmol). 1H NMR (300 MHz, CDCl3): δ 4.81 (s, 2H), 5.12 (t, 1H), 7.34 (d, 2H, J 


















Procedure: (5-Nitrofuran-2-yl)methanol (0.120 g, 0.838 mmol) was dissolved in THF (3.5 mL) 
at -78oC and had LHMDS (1.0M in THF, 0.838 mmol) was added dropwise.  The mixture was 
stirred for 30 min.  In a separate flask, (2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-
(chloro((4-chlorobutyl)(methyl)amino)phosphoryl)-4,4-difluorobutyl acetate (0.310 g, 0.525 
mmol) was cooled to -78oC in THF (3.5 mL).  The alkoxide was then added to the phosphoryl 
chloride dropwise.  The reaction was then allowed to proceed for 15 h.  At this time, sat. NH4Cl 
(2 mL) was added to quench the reaction.  The solution was then extracted with EtOAc (3x5 mL).  
This was then dried over Na2SO4 and concentrated under reduced pressure.  The  product was 
purified by flash silica chromatography to yield (2S)-2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-4-(((4-chlorobutyl)(methyl)amino)((5-nitrofuran-2-
yl)methoxy)phosphoryl)-4,4-difluorobutyl acetate in 68% yield (0.250 g, 0.359 mmol) as a pale 
yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.75 (d, 2H, J= 7.4 Hz), 7.57 (d, 2H, J= 7.4 Hz), 7.38 
(t, 2H, J= 7.4 Hz), 7.27 (m, 3H), 6.67 (m, 1H), 5.33 (m, 1H), 5.06 (m, 1H), 4.32 (m, 6H), 3.55 
(m, 2H), 2.73 (d, 3H, J= 9.1 Hz), 2.52 (m, 2H), 2.07 (s, 3H), 1.73-1.68 (m, 4H)  31P NMR 
(CDCl3), δ 9.3 (dd, J= 112, 94 Hz; minor), δ 9.5 (dd, J= 112, 94 Hz; major), 19F NMR (CDCl3) δ 
















Procedure: A solution of (2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(((4-
chlorobutyl)(methyl)amino)((5-nitrofuran-2-yl)methoxy)phosphoryl)-4,4-difluorobutyl acetate 
(0.250 g, 0.359 mmol) was dissolved in MeOH (15 mL) and cooled to -4oC and K2CO3 (0.016 g, 
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0.118 mmol) was then added.  The reaction mixture was stirred for 15 h at this temperature.  The 
solution was then quenched with cold sat. NH4Cl (5 mL).  This solution was then diluted with 
EtOAc (35 mL), and separated.  The NH4Cl solution was back washed with EtOAc (3x15 mL) 
and dried over Na2SO4.  The product was then purified by column chromatography to yield 70% 
(9H-fluoren-9-yl)methyl ((2S)-4-(((4-chlorobutyl)(methyl)amino)((5-nitrofuran-2-
yl)methoxy)phosphoryl)-4,4-difluoro-1-hydroxybutan-2-yl)carbamate (0.114 g, 0.175 mmol) as a 
colorless oil. 1H NMR (300 MHz, CDCl3) 7.75 (d, 2H, J= 7.4 Hz), 7.58 (d, 2H, J= 7.4 Hz), 7.39, 
(t, 2H, J= 7.4 Hz), 7.29 (t, 2H J= 7.4 Hz), 7.23 (d, 1H J= 3.6 Hz), 6.66 (d, 1H, J= 3.6 Hz), 5.59 
(m, 1H), 5.07 (t, 2H, J= 8.0 Hz), 4.47 (m, 4H), 3.73 (m, 2H), 3.55 (m, 2H), 3.53 (m, 2H), 3.18 
(m, 2H), 2.73 (d, 3H, J= 9.1 Hz), 2.41 (m, 2H), 1.71 (m, 2H) 31P NMR (CDCl3) δ –10.7 (t, J= 112 



















yl)methoxy)phosphoryl)-4,4-difluoro-1-hydroxybutan-2-yl)carbamate  (0.300 g, 0.479 mmol) 
was dissolved in acetone (45 mL).  The reaction was cooled to -25oC.  To this solution Jones 
reagent (3 mL, 2.5M, 1.20 mmol) was added dropwise until the color was maintained a dark blue-
green color.  This was kept at 12 h at 0oC and was quenched with i-PrOH (4 mL).  The solution 
was filtered through celite and concentrated.  The product was then purified by flash silica 
chromatography.  (2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(((4-
chlorobutyl)(methyl)amino)((5-nitrofuran-2-yl)methoxy)phosphoryl)-4,4-difluorobutanoic acid  
was isolated in 65% yield (0.208 g, 0.311 mmol) as a pale yellow oil. 1H NMR (300 M, CDCl3) δ 
7.74 (d, 2H, J= 7.3 Hz), 7.58 (m, 2H), 7.37 (t, 2H, J= 7.3 Hz), 7.25 (m, 3H), 6.68 (m, 1H), 5.90 
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(m, 1H), 5.11 (m, 2H), 4.29 (m, 3H), 3.53 (m, 2H), 3.16 (m, 2H), 2.72 (m, 5H), 1.71 (m, 4H) 31P 
NMR (CDCl3) δ 9.3 (dd, J= 112, 94 Hz; minor), δ 9.5 (dd, J = 112, 94 Hz; major), 19F NMR 




















chlorobutyl)(methyl)amino)((5-nitrofuran-2-yl)methoxy)phosphoryl)-4,4-difluorobutanoic acid  
(0.32 g, 0.479 mmol) was dissolved in DCM (10 mL) and cooled to 0oC. PyBOP (0.281 g, 0.54 
mmol) was then added and stirred for 10 min.  To this tyramine (0.074 g, 0.54 mmol) was added 
in one portion followed by DIPEA (0.213 mL 1.22 mmol).  The reaction proceeded for 30 min, 
followed by quenching with sat. NH4Cl (4 mL).  This was then extracted with DCM (3x5 mL) 
and the combined organic layers were dried over Na2SO4.  The DCM was then removed under 
reduced pressure and purified by flash silica chromatography. This gave (9H-fluoren-9-yl)methyl 
((2S)-4-(((4-chlorobutyl)(methyl)amino)((5-nitrofuran-2-yl)methoxy)phosphoryl)-4,4-difluoro-1-
((4-hydroxyphenethyl)amino)-1-oxobutan-2-yl)carbamate in a 66% yield (0.250 g, 0.317 mmol) 
as a pale yellow oil.  1H NMR (300 MHz, CD3OD) δ  7.93 (t, 1H, J= 5.5 Hz), 7.76 (d, 2H, J= 7.5 
Hz), 7.63 (d, 2H, J= 7.5 Hz), 7.52 (m, 1H), 7.26 (m, 5H), 7.00 (d, 2H, J = 8.3), 6.82 (t, 1H, J= 4.3 
Hz), 6.69 (d, 2H, J= 8.3 Hz), 5.15 (d, 2H, J= 9.3 Hz), 4.35 (m, 4H), 3.55 (t, 2H, J= 5.5 Hz), 3.17 
(m, 4H), 2.72 (d, 3H, J= 9.1 Hz), 2.66 (t, 2H, J= 7.2 Hz), 2.44 (m, 2H), 1.79-1.62 (m, 4H) 31P 
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NMR (CDCl3) δ 9.3 (dd, J= 112, 94 Hz; minor), δ 9.5 (dd, J = 112, 94 Hz; major), 19F NMR 



















yl)carbamate (0.500 g, 0.634 mmol) was dissolved in DCM (5 mL)and cooled to 0oC. To this 
DBU (0.094 g, 0.698 mmol) was added and allowed to stir at this temperature for 22 h.  The 
reaction was quenched with brine (2 mL) and extracted with DCM (3x5 mL).  The extracted 
partitions were dried over Na2SO4.  This was then concentrated and purified by flash silica 
column chromatography to yield (5-nitrofuran-2-yl)methyl P-((S)-3-amino-1,1-difluoro-4-((4-
hydroxyphenethyl)amino)-4-oxobutyl)-N-(4-chlorobutyl)-N-methylphosphonamidate in a 66% 
yield (0.240 g 0.434 mmol) as a pale yellow oil. 1H NMR (300 MHz, CD3OD) δ 7.44 (d, 1H, J= 
3.7 Hz), 7.03 (d, 2H, J= 8.2 Hz), 6.89 (d, 1H, J= 3.7 Hz), 6.70 (d, 2H, J= 8.3 Hz), 5.20 (d, 2H, J= 
9.1 Hz), 3.68 (m, 1H), 3.59 (t, 2H, J= 5.8 Hz), 3.39 (m, 2H), 3.15 (m, 2H), 2.75 (d, 3H, J= 9.1 
Hz), 2.69 (t, 2H, J= 7.4 Hz), 2.54 (m, 1H), 2.19 (m, 1H), 1.75 (m, 4H) 31P NMR (CDCl3) δ 9.3 
(dd, J= 112, 94 Hz; minor), δ 9.5 (dd, J= 112, 94 Hz; major), 19F NMR (CDCl3) δ -112.4 (q-d, J= 










Procedure:1-Acetylindoline-4-carboxylic acid (0.100 g 0.488 mmol) was dissolved in THF (2 
mL).  The solution was then placed in a water bath.  To this solution HOBt (0.134 g, 0.976 mmol 
(2 eq)) and DIC (0.122 g 0.976 mmol (2 eq)) were added.  The solution was allowed 30 min to 
react.  Following this ethyl glycine hydrochloride (0.136 g, 0.976 mmol (2 eq)) was added in one 
portion, followed by DIPEA (0.138 g, 1.07 mmol (2.2 eq)) dropwise.  The reaction was allowed 
to proceed for 18 h.  The volume of the mixture was then reduced and redissolved in DCM (5 
mL).  This was washed with sat. NH4Cl (7 mL), followed by sat. NaHCO3 (7 mL), where each 
was backwashed with DCM (3x5 mL) and concentrated between washes.  The resulting product 
was purified by silica flash chromatography and resulted in ethyl 2-(1-formylindoline-4-
carboxamido)acetate in a 97% yield (0.138 g, 0.478 mmol).1H NMR (300 MHz, CDCl3) δ  8.97 
(d, 1H, J= 4.1 Hz), 8.80 (d, 1H, J= 8.5 Hz), 8.22 (d, 1H, J=1.4 Hz), 7.81 (t, 1H, J= 7.2 Hz), 7.70 
(d, 1H, J=7.2 Hz), 7.48 (t, 1H, J= 8.6, 4.1 Hz), 7.06 (br-s, 1H) 4.39 (q, 2H, J= 7.1 Hz), 4.02(s, 








Procedure: 1-Acetylindoline-4-carboxylic acid (0.100 g 0.488 mmol) was dissolved in THF (2 
mL).  The solution was then placed in a water bath.  To this solution HOBt (0.134 g, 0.976 mmol 
(2 eq)) and DIC (0.122 g 0.976 mmol (2 eq)) were added.  The solution was allowed 30 min to 
react.  Following this ethyl glycine hydrochloride (0.136 g, 0.976 mmol (2 eq)) was added in one 
portion, followed by DIPEA (0.138 g, 1.07 mmol (2.2 eq)) dropwise.  The reaction was allowed 
to proceed for 18 h.  The volume of the mixture was then reduced and redissolved in DCM (5 
mL).  This was washed with sat. NH4Cl (7 mL), followed by sat. NaHCO3 (7 mL), where each 
was backwashed with DCM (3x5 mL) and concentrated between washes.  The resulting product 
was purified by silica flash chromatography and resulted in ethyl 2-(1-formylindoline-4-
carboxamido)acetate in a 95% yield (0.135 g, 0.463 mmol). 1H NMR (300 MHz, CDCl3) δ 9.30 
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(s, 1H, J= 1.0 Hz), 8.62 (d, 1H, J= 6.0 Hz), 8.25 (d, 1H, J=6.0 Hz), 8.08 (d, 1H, J= 8.2 Hz), 8.96 
(d, 1H, J= 7.2 Hz), 7.62 (dd, 1H, J= 8.2, 7.2 Hz), 7.00 (br-s, 1H, J= 5.2 Hz), 4.39 (q, 2H, J= 7.1 









Procedure: To a solution of coupling product 33 (0.138 g, 0.478 mmol) in THF (10 mL) and 
water (3 mL) was added NaOH (20 mg, 0.478 mmol) and heated to 80oC for 30 min.  The THF 
was removed under reduced pressure, and 1N HCl solution was added.  The reaction mixture was 
extracted with EtOAc (3 X 5 mL), dried over Na2SO4.  This was then concentrated and 
purification by column chromatography to afford the acid. (0.099 mg, 0.431 mmol) as a solid in a 
90% yield. 1H NMR (300 MHz, MeOD) δ  8.97 (d, 1H, J= 4.1 Hz), 8.80 (d, 1H, J= 8.5 Hz), 8.22 
(d, 1H, J=1.4 Hz), 7.81 (t, d 1H, J= 7.2, 1.4 Hz), 7.70 (d, 1H, J=7.2 Hz), 7.48 (t, 1H, J= 8.6, 4.1 








Procedure: To a solution of coupling product 34 (0.135 g, 0.463 mmol) in THF (10 mL) and 
water (3 mL) was added NaOH (20 mg, 0.478 mmol) and heated to 80oC for 30 min.  The THF 
was removed under reduced pressure, and 1N HCl solution was added.  The reaction mixture was 
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extracted with EtOAc (3 X 5 mL), and dried over Na2SO4.  This was then concentrated and 
purification by column chromatography to afford the acid (0.086 mg, 0.375 mmol) as a solid in a 
81% yield.1H NMR (300 MHz, MeOD) δ 9.30 (s, 1H, J= 1.0 Hz), 8.62 (d, 1H, J= 6.0 Hz), 8.25 
(d, 1H, J=6.0 Hz), 8.08 (d, 1H, J= 8.2 Hz), 8.96 (d, 1H, J= 7.2 Hz), 7.62 (dd, 1H, J= 8.2, 7.2 Hz), 






Procedure:  1H-Indole-4-carboxylic acid (0.805 g, 5 mmol) is dissolved in dry MeOH (in 150 
mL). To this conc. sulfuric acid (5 drops  ≈0.25 mL) was and the reaction mixture was refluxed 
for 24 h.  The reaction was then cooled to room temperature and MeOH was removed.  The 
resulting solution was then dissolved in dichloromethane (30 mL) and saturated sodium 
bicarbonate solution was added until pH 8 in order to remove residual starting material.  The 
DCM was extracted and the aqueous phase washed (3X 30 mL), dried over MgSO4 and the then 
concentrated in vacuo resulting in methyl 1H-indole-4-carboxylate in quantitative yield (0.875g, 
5 mmol) as a red oil. 1H NMR (300 MHz, CDCl3) δ 9.27 (br-s, 1H), 7.95 (d, 1H, J= 4.9 Hz), 7.92 








Procedure: Methyl 1H-indole-4-carboxylate (1.75 g, 10 mmol) was dissolved in acetic acid (37.5 
mL).  To this perchloric acid (11 mL) was added.  The reaction vessel was sealed and purged with 
argon.  Next, Pd/C 10% was added in one portion and quickly resealed, then repurged with argon.  
Then a hydrogen balloon was attached and the reaction was allowed to proceed for 24 h.  The 
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reaction was again purged with argon and DCM (40 mL) was added.  This was then filtered 
through celite and sat NaHSO4 (20 mL) was then added in several portions.  Additional NaHSO4 
was added in small portions until reactivity ceased.  The reaction mixture was separated and 
further extracted with DCM (2X25 mL).  This was concentrated and purified by flash silica 
chromatography.   Methyl indoline-4-carboxylate was isolated in a 69% yield (1.22 g, 6.9 mmol) 
as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 7.30 (t, 1H, J= 6 Hz), 7.00 (t, 1H, J= 9 Hz), 7.39 







1-tert-Butyl 4-methyl indoline-1,4-dicarboxylate 
Procedure: Methyl indoline-4-carboxylate (0.163 g, 0.923 mmol) is dissolved in THF (5 mL), 
and di-tert-butyl dicarbonate (0.222 g, 1.02 mmol (1.1 eq)) is added. This is then taken down to 
0oC and DIPEA (0.337 mL 1.94 mmol (2.10 eq)) was added dropwise followed by DMAP (cat.).  
This was immediately brought to room temperature following addition and allowed to proceed for 
15 h.  The reaction was quenched with saturated ammonium chloride (2 mL).  DCM added (3X15 
mL) and separated.  The resulting product was then concentrated and purified by flash silica 
chromatography in a 98% yield of 1-tert-butyl 4-ethyl 1H-indole-1,4-dicarboxylate (0.240 g, 
0.912 mmol) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 8.45 (d, 1H, J= 8.4 Hz), 7.67 (d, 1H, 
J= 7.5 Hz), 7.28 (q, 1H, J= 8.9 Hz), 4.10 (t, 2H, J= 8.6 Hz), 3.90 (s, 3H), 3.57 (t, 2H, J=8.6 Hz), 










Procedure: 1H-Indole-4-carboxylate (0.253 g, 1.37 mmol) is dissolved in THF (5 mL), and di-
tert-butyl dicarbonate (0.329 g, 1.51 mmol (1.1 eq)) is added. This is then taken down to 0oC and 
NEt3 (0.381mL, 2.74 mmol (2 eq)) was added dropwise followed by DMAP (cat.).  This was 
immediately brought to room temperature following addition and allowed to proceed for 15 h.  
The reaction was quenched with saturated ammonium chloride (2 mL).  DCM added (3X15 mL) 
and separated.  The resulting product was then concentrated and purified by flash silica 
chromatography in a 61% yield 1-tert-butyl 4-methyl 1H-indole-1,4-dicarboxylate as a red oil 
(0.240 g, 0.830 mmol). 1H NMR (300 MHz, CDCl3) δ 7.93 (d, 1H, J= 4.9 Hz), 7.92 (d, 1H, J= 







Procedure: Methyl indoline-4-carboxylate (0.163 g, 0.923 mmol) is dissolved in THF (5 mL), 
and di-tert-butyl dicarbonate (0.222 g, 1.02 mmol (1.1 eq)) is added. This is then taken down to 
0oC and DIPEA (0.337 mL 1.94 mmol (2.10 eq)) was added dropwise followed by DMAP (cat.).  
This was immediately brought to room temperature following addition and allowed to proceed for 
15 h.  The reaction was quenched with saturated ammonium chloride (2 mL).  DCM added (3X15 
mL) and separated.  The resulting product was then concentrated and purified by flash silica 
chromatography in a 98% yield methyl 1-acetylindoline-4-carboxylate as a dark yellow oil (0.260 
g 1.18 mmol).1H NMR (300 MHz, CDCl3) δ 8.37 (d, 1H, J= 8.1 Hz), 7.60 (d, 1H, J= 7.9 Hz), 










Procedure:  Formic acid was dissolved in THF (5 mL).  To this DCC (0.210 g 1.02 mmol (1.1 
eq) was added and allowed to react for 30 min followed by dropwise addition of DIPEA (0.158 
mL 1.94 mmol).  Methyl indoline-4-carboxylate (0.163 g, 0.923 mmol) in 2 mL of THF was then 
added.  This was then allowed to react for 15 h.  The reaction was quenched with sat. NH4Cl (5 
ML).  Then DCM (3X10 mL) was used to extract the solution, which was then concentrated in 
vacuo.  This was then purified by silica flash chromatography resulting in methyl 1-
formylindoline-4-carboxylate in a 68% yield (0.128 g 0.628 mmol) as a dark yellow oil. 1H NMR 
(300 MHz, CDCl3) δ 8.88 (s, 1H), δ  8.18 (d, 1H, J= 8.4 Hz), 7.63 (d, 1H, J= 7.5 Hz), 7.23 (q, 1H, 








Procedure: 1-tert-Butyl 4-methyl 1H-indole-1, 4-dicarboxylate (0.240 g, 0.912 mmol) was taken 
into a flask with DCM (2 mL).  To this a solution of 2M KOH in MeOH was added (2 mL). 
MeOH solution was prepared from non-dried solvent.  This reaction was stirred for 8 h and the 
volume was reduced and redissolved in DCM (2 mL), followed by addition of H2O (3 mL).  The 
resulting mixture was then extracted with DCM (2x2 mL).  This was saved then the aqueous 
phase was acidified dropwise with 1 M HCl (≈4 mL).  This was then extracted with DCM (3X10 
mL) and concentrated.  The crude product of 1-(tert-butoxycarbonyl)indoline-4-carboxylic acid 
was isolated in a 96% (0.230 g 0.875 mmol) and used directly in the next step. 1H NMR (300 
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MHz, CDCl3) δ  8.45 (d, 1H, J= 8.4 Hz), 7.67 (d, 1H, J= 7.5 Hz), 7.28 (q, 1H, J= 8.9 Hz), 4.10 (t, 







Procedure: Methyl 1-acetylindoline-4-carboxylate (0.260 g 1.18 mmol) was dissolved in DCM 
(2 mL).  To this a solution of 2M KOH in MeOH was added (2 mL). MeOH solution was 
prepared from non-dried solvent.  This reaction was stirred for 8 h and the volume was reduced 
and re-dissolved in DCM (2 mL), followed by addition of H2O (3 mL).  The resulting mixture 
was then extracted with DCM (2x2 mL).  This was saved then the aqueous phase was acidified 
dropwise with 1 M HCl (≈4 mL).  This was then extracted with DCM (3X10 mL) and 
concentrated.  The crude product of 1-acetylindoline-4-carboxylic acid was isolated in a 41% 
(0.100 g 0.488 mmol) yield and used directly in the next step. 1H NMR (300 MHz, CDCl3) δ 8.37 









Procedure Methyl 1-formylindoline-4-carboxylate (0.128 g 0.628 mmol) was dissolved in DCM 
(2 mL).  To this a solution of 2M KOH in MeOH was added (2 mL). MeOH solution was 
prepared from non-dried solvent.  This reaction was stirred for 8 h and the volume was reduced 
and re-dissolved in DCM (2 mL), followed by addition of H2O (3 mL).  The resulting mixture 
was then extracted with DCM (2x2 mL).  This was saved then the aqueous phase was acidified 
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dropwise with 1 M HCl (≈4 mL).  This was then extracted with DCM (3X10 mL) and 
concentrated.  The crude product of 1-formylindoline-4-carboxylic acid was isolated in a 94% 
(0.120 g 0.628 mmol) and used directly in the next step. 1H NMR (300 MHz, CDCl3) δ 8.90 (s, 
1H), 8.17 (d, 1H, J = 8.4 Hz), 7.65 (d, 1H, J= 7.5 Hz), 7.25 (q, 1H, J= 8.9 Hz), 4.18 (t, 2H, J= 











Procedure: 1-(tert-Butoxycarbonyl)indoline-4-carboxylic acid (0.230 g 0.875 mmol) was 
dissolved in THF (2 mL).  The solution was then placed in a water bath.  To this solution HOBt 
(0.205 g, 1.52 mmol (1.7 eq)) and DIC (0.191 g 1.52 mmol (1.7 eq)) were added.  The solution 
was allowed 30 min to react.  Following this ethyl glycine hydrochloride (0.212 g, 1.52 mmol 
(1.7 eq)) was added in one portion, followed by DIPEA (0.178 g, 1.90 mmol (2.2 eq)) dropwise.  
The reaction was allowed to proceed for 18 h.  The volume of the mixture was then reduced and 
redissolved in DCM (5 mL).  This was washed with sat. NH4Cl (7 mL), followed by sat. NaHCO3 
(7 mL), where each was backwashed with DCM (3x5 mL) and concentrated between washes.  
The resulting product was purified by silica flash chromatography and resulted in tert-butyl 4-((2-
ethoxy-2-oxoethyl)carbamoyl)indoline-1-carboxylate in a 92% yield (0.279 g, 0.802 mmol) as a 
pale yellow oil.1H NMR (300 MHz, CDCl3) δ 8.45 (d, 1H, J= 8.4 Hz), 7.67 (d, 1H, J= 7.5 Hz), 
7.28 (q, 1H, J= 8.9 Hz), 6.82 (br s, 1H), 4.22 (q, 2H, J= 7.1 Hz), 4.16 (s, 2H), 4.12 (t, 2H, J= 8.6 












Procedure: 1-Acetylindoline-4-carboxylic acid (0.100 g 0.488 mmol) was dissolved in THF (2 
mL).  The solution was then placed in a water bath.  To this solution HOBt (0.134 g, 0.976 mmol 
(2 eq)) and DIC (0.122 g 0.976 mmol (2 eq)) were added.  The solution was allowed 30 min to 
react.  Following this ethyl glycine hydrochloride (0.136 g, 0.976 mmol (2 eq)) was added in one 
portion, followed by DIPEA (0.138 g, 1.07 mmol (2.2 eq)) dropwise.  The reaction was allowed 
to proceed for 18 h.  The volume of the mixture was then reduced and redissolved in DCM (5 
mL).  This was washed with sat. NH4Cl (7 mL), followed by sat. NaHCO3 (7 mL), where each 
was backwashed with DCM (3x5mL) and concentrated between washes.  The resulting product 
was purified by silica flash chromatography and resulted in ethyl 2-(1-formylindoline-4-
carboxamido)acetate in a 97% yield as a pale yellow oil (0.138 g, 0.478 mmol). 1H NMR (300 
MHz, CDCl3) δ 8.37 (d, 1H, J= 8.1 Hz), 7.60 (d, 1H, J= 7.9 Hz), 7.21 (q, 1H, J= 8.9 Hz), 4.22 (t, 











Procedure: 1-Formylindoline-4-carboxylic acid (0.120 g 0.628 mmol) was dissolved in THF (2 
mL).  The solution was then placed in a water bath.  To this solution HOBt (0.169 g, 1.26 mmol 
(2 eq)) and DIC (0.158 g 1.26 mmol (2 eq)) were added.  The solution was allowed 30 min to 
react.  Following this ethyl glycine hydrochloride (0.068 g, 1.26 mmol (2 eq)) was added in one 
portion, followed by DIPEA (0.178 g, 1.38 mmol (2.2 eq)) dropwise.  The reaction was allowed 
to proceed for 18 h.  The volume of the mixture was then reduced and redissolved in DCM (5 
mL).  This was washed with sat. NH4Cl (7 mL), followed by sat. NaHCO3 (7 mL), where each 
was backwashed with DCM (3x5mL) and concentrated between washes.  The resulting product 
was purified by silica flash chromatography and resulted in ethyl 2-(1-formylindoline-4-
carboxamido)acetate in a 89% yield as a pale yellow oil (0.153 g, 0.557 mmol).1H NMR (300 
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MHz, CDCl3) δ 8.90 (s, 1H), 8.02 (d, 1H, J= 8.4 Hz), 7.76 (d, 1H, J= 7.5 Hz), 7.25 (q, 1H, J= 8.9 












Procedure: 1-(tert-Butoxycarbonyl)-1H-indole-4-carboxylic acid (0.200 g, 0.760 mmol) was 
dissolved in THF (2 mL).  The solution was then placed in a water bath.  To this solution HOBt 
(0.205 g, 1.52 mmol (2.0 eq)) and DIC (0.191 g 1.52 mmol (2.0 eq)) were added.  The solution 
was allowed 30 min to react.  Following this ethyl glycine hydrochloride (0.212 g, 1.52 mmol 
(2.0 eq)) was added in one portion, followed by DIPEA (0.178 g, 1.90 mmol (2.5 eq)) dropwise.  
The reaction was allowed to proceed for 18 h.  The volume of the mixture was then reduced and 
redissolved in DCM (5 mL).  This was washed with sat. NH4Cl (7 mL), followed by sat. NaHCO3 
(7 mL), where each was backwashed with DCM (3x5 mL) and concentrated between washes.  
The resulting product was purified by silica flash chromatography and resulted in tert-butyl 4-((2-
ethoxy-2-oxoethyl)carbamoyl)-1H-indole-1-carboxylate in a 92% yield as a pale yellow oil 
(0.240 g, 0.693 mmol). 1H NMR (300 MHz, CDCl3) δ 7.93 (d, 1H, J= 4.9 Hz), 7.92 (d, 1H, J= 
4.9 Hz), 7.63 (d, 1H, J= 3.2 Hz), 7.27 (d, 1H, J= 3.2 Hz), 7.18 (t, 1H, J= 5.2 Hz), 6.94 (br s, 1H), 











Procedure:  tert-Butyl 4-((2-ethoxy-2-oxoethyl)carbamoyl)indoline-1-carboxylate (0.279 g, 
0.802 mmol) was dissolved in DCM (1 mL).  To this a solution of 2M KOH in MeOH was added 
(4 mL). MeOH solution was prepared from non-dried solvent.  This reaction mixture was stirred 
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for 8 h and the volume was reduced and re-dissolved in DCM (2 mL), followed by addition of 
H2O (3 mL).  The resulting mixture was then extracted with DCM (2x2 mL).  This was saved 
then the aqueous phase was acidified dropwise with 1 M HCl (≈8 mL).  This was then extracted 
with DCM (3X10 mL) and concentrated.  The crude product of 1-(tert-butoxycarbonyl)-1H-
indole-4-carboxylic acid was isolated in 23% yield as a pale yellow oil (0.060 g, 0.182 mmol) and 
used directly in the next step.  Additionally, 20% of the starting material was isolated from the 
initial DCM wash. 1H NMR (300 MHz, CDCl3) δ 8.45 (d, 1H, J= 8.4 Hz), 7.67 (d, 1H, J= 7.5 
Hz), 7.28 (q, 1H, J= 8.9 Hz), 6.82 (br s, 1H), 4.16 (s, 2H), 4.12 (t, 2H, J = 8.6 Hz, 2H), 3.55 (t, 











Procedure: Ethyl 2-(1-formylindoline-4-carboxamido)acetate (0.138 g, 0.478 mmol) was 
dissolved in DCM (1 mL).  To this a solution of 2M KOH in MeOH was added (4 mL). MeOH 
solution was prepared from non-dried solvent.  This reaction mixture was stirred for 8 h and the 
volume was reduced and re-dissolved in DCM (2 mL), followed by addition of H2O (3 mL).  The 
resulting mixture was then extracted with DCM (2x2 mL).  This was saved then the aqueous 
phase was acidified dropwise with 1 M HCl (≈8 mL).  This was then extracted with DCM (3X10 
mL) and concentrated.   The crude product of 2-(1-acetylindoline-4-carboxamido)acetic acid was 
isolated in 60% yield as a pale yellow oil (0.090 g, 0.343 mmol) and used directly in the next 
step. 1H NMR (300 MHz, CDCl3) δ 8.37 (d, 1H, J= 8.1 Hz), 7.60 (d, 1H, J= 7.9 Hz), 7.21 (q, 1H, 














Procedure: Ethyl 2-(1-formylindoline-4-carboxamido)acetate (0.153 g, 0.557 mmol) was 
dissolved in DCM (1 mL).  To this a solution of 2M KOH in MeOH was added (4 mL). MeOH 
solution was prepared from non-dried solvent.  This reaction mixture was stirred for 8 h and the 
volume was reduced and re-dissolved in DCM (2 mL), followed by addition of H2O (3 mL).  The 
resulting mixture was then extracted with DCM (2x2 mL).  This was saved then the aqueous 
phase was acidified dropwise with 1 M HCl (≈8 mL).  This was then extracted with DCM (3X10 
mL) and concentrated.   The crude product of 2-(1-formylindoline-4-carboxamido)acetic acid was 
isolated in 60% yield as a pale yellow oil (0.080 g, 0.332 mmol) and used directly in the next 
step. 1H NMR (300 MHz, CDCl3) δ 8.90 (s, 1H), 8.02 (d, 1H, J= 8.4 Hz), 7.76 (d, 1H, J= 7.5 Hz), 











Procedure: tert-Butyl 4-((2-ethoxy-2-oxoethyl)carbamoyl)-1H-indole-1-carboxylate (0.240 g, 
0.693 mmol) was dissolved in DCM (1 mL).  To this a solution of 2M KOH in MeOH was added 
(4 mL). MeOH solution was prepared from non-dried solvent.  This reaction mixture was stirred 
for 8 h and the volume was reduced and re-dissolved in DCM (2mL), followed by addition of 
H2O (3 mL).  The resulting mixture was then extracted with DCM (2x2 mL).  This was saved 
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then the aqueous phase was acidified dropwise with 1 M HCl (≈8 mL).  This was then extracted 
with DCM (3X10 mL) and concentrated.  The crude product of 1-(tert-butoxycarbonyl)-1H-
indole-4-carboxylic acid was isolated in 54% yield as a pale yellow oil (0.120 g, 0.377 mmol) and 
used directly in the next step.  Additionally, 15% of the starting material was isolated from the 
initial DCM wash. 1H NMR (300 MHz, CDCl3) δ 7.93 (d, 1H, J= 4.9 Hz), 7.92 (d, 1H, J= 4.9 
Hz), 7.63 (d, 1H, J= 3.2 Hz), 7.27 (d, 1H, J= 3.2 Hz), 7.18 (t, 1H, J= 5.2 Hz), 6.94 (br s, 1H), 























Procedure:  Acid (160 mg, 0.142 mmol) 46a is dissolved in THF which had PyBop (0.073 mg, 
0.142 mmol) added to it and allowed to react for 30 min.  Amine 29 (40 mg, 0.0707 mmol) is 
dissolved in another portion of THF/DCM.  The two portions are combined and allowed to react 
another 30 min.  Following this DIPEA (0.02 µg, 0.142mmol) was added and the reaction 
proceeded 18 h.  The mixture was quenched with sat. NH4Cl (2 mL).  This was extracted with 
DCM (3x5 mL), concentrated, and purified by flash chromatography to afford 48a in a 54% yield 
as a dark yellow oil (33 mg, 0.038 mmol).1H NMR (300 MHz, CDCl3) δ 8.45 (d, 1H, J= 8.4 Hz), 
7.67 (d, 1H, J= 7.5 Hz), 7.44 (d, 1H, J= 3.7 Hz), 7.28 (q, 1H, J= 8.9 Hz), 7.03 (d, 2H, J= 8.2 Hz), 
6.82 (br s, 1H), 6.70 (br d, 2H, J= 8.3 Hz), 5.20 (d, 2H, J= 9.1 Hz), 4.16 (s, 2H), 4.12 (t, 2H, J= 
8.6 Hz, 2H), 3.68 (m, 1H), 3.59 (t, 2H, J= 5.8 Hz), 3.55 (t, 2H, J= 8.6 Hz), 3.39 (m, 2H), 3.15 (m, 
2H), 2.75 (d, 3H, J= 9.1 Hz), 2.69 (t, 2H, J= 7.4 Hz), 2.54 (m, 1H), 2.19 (m, 1H), 1.75 (m, 4H), 
1.16 (s, 9H) 31P NMR (CDCl3) δ 9.3 (dd, J = 112, 94 Hz; minor), δ 9.5 (dd, J = 112, 94 Hz; 























Procedure:  Acid (160 mg 0.142 mmol) 46b is dissolved in THF which had PyBop (0.073 mg 
0.142 mmol) added to it and allowed to react for 30 min.  Amine 29 (40 mg 0.0707 mmol) is 
dissolved in another portion of THF/DCM.  The two portions are combined and allowed to react 
another 30 min.  Following this DIPEA (0.02 µg 0.142 mmol) was added and the reaction 
proceeded 18 h.  The mixture was quenched with sat. NH4Cl (2 mL).  This was extracted with 
DCM (3x5 mL), concentrated, and purified by flash chromatography to afford 48b in a 63% yield 
as a dark yellow oil (36 mg, 0.045 mmol).1H NMR (300 MHz, CDCl3) δ 8.45 (d, 1H, J= 8.4 Hz), 
7.67 (d, 1H, J= 7.5 Hz), δ 7.44 (d, 1H, J= 3.7 Hz), 7.28 (q, 1H, J= 8.9 Hz), 7.03 (d, 2H, J= 8.2 
Hz), 6.82 (br s, 1H), 6.70 (br d, 2H, J= 8.3 Hz), 5.20 (d, 2H, J= 9.1 Hz), 4.16 (s, 2H), 4.12 (t, 2H, 
J= 8.6 Hz, 2H), 3.68 (m, 1H), 3.59 (t, 2H, J= 5.8 Hz), 3.55 (t, 2H, J= 8.6 Hz), 3.39 (m, 2H), 3.15 
(m, 2H), 2.75 (d, 3H, J= 9.1 Hz), 2.69 (t, 2H, J= 7.4 Hz), 2.54 (m, 1H), 2.26 (s, 3H), 2.19 (m, 
1H), 1.75 (m, 4H), 31P NMR (CDCl3) δ 9.3 (dd, J= 112, 94 Hz; minor), δ 9.5 (dd, J= 112, 94 Hz; 

























Procedure:  Acid (80 mg 0.0707 mmol) 46c is dissolved in THF which had PyBop (0.036 mg 
0.0707 mmol) added to it and allowed to react for 30 min.  Amine 29 (20 mg 0.035 mmol) is 
dissolved in another portion of THF/DCM.  The two portions are added and allowed to react 
another 30 min.  Following this DIPEA (0.01 µg, 0.0707 mmol) was added and the reaction 
proceeded 18 h.  The mixture was quenched with sat. NH4Cl (2 mL).  This was extracted with 
DCM (3x5 mL), concentrated, and purified by flash chromatography to afford 48c in a 54% yield 
as a dark yellow oil (54mg, 0.019mmol).1H NMR (300 MHz, CDCl3) δ 8.90 (s, 1H), 8.45 (d, 1H, 
J= 8.4 Hz), 7.67 (d, 1H, J= 7.5 Hz), δ 7.44 (d, 1H, J= 3.7 Hz), 7.28 (q, 1H, J= 8.9 Hz), 7.03 (d, 
2H, J= 8.2 Hz), 6.82 (br s, 1H), 6.70 (br d, 2H, J= 8.3 Hz), 5.20 (d, 2H, J= 9.1 Hz), 4.16 (s, 2H), 
4.12 (t, 2H, J= 8.6 Hz, 2H), 3.68 (m, 1H), 3.59 (t, 2H, J= 5.8 Hz), 3.55 (t, 2H, J =8.6 Hz), 3.39 
(m, 2H), 3.15 (m, 2H), 2.75 (d, 3H, J= 9.1 Hz), 2.69 (t, 2H, J= 7.4 Hz), 2.54 (m, 1H), 2.19 (m, 
1H), 1.75 (m, 4H), 31P NMR (CDCl3) δ 9.3 (dd, J= 112, 94 Hz; minor), δ 9.5 (dd, J= 112, 94 Hz; 























Procedure: Acid (160 mg 0.142 mmol) 46d is dissolved in THF which had PyBop (0.073 mg 
0.142 mmol) added to it and allowed to react for 30 min.  While amine 29 (40 mg 0.0707 mmol) 
is dissolved in another portion of THF/DCM.  The two portions are added and allowed to react 
another 30 min.  Following this DIPEA (0.02 µg 0.142 mmol) was added and the reaction 
proceeded 18 h.  The mixture was quenched with sat. NH4Cl (2 mL).  This was extracted with 
DCM (3x5 mL), concentrated, and purified by flash chromatography to afford 48d in a 82% yield 
as a dark yellow oil (53 mg 0.062 mmol).  1H NMR (300 MHz, CDCl3) δ 7.93 (d, 1H, J= 4.9 Hz), 
7.92 (d, 1H, J= 4.9 Hz), 7.63 (d, 1H, J= 3.2 Hz), δ 7.44 (d, 1H, J= 3.7 Hz), 7.27 (d, 1H, J= 3.2 
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Hz), 7.18 (t, 1H, J= 5.2 Hz), 7.03 (d, 2H, J= 8.2 Hz), 6.94 (br s, 1H), 6.70 (d, 2H, J= 8.3 Hz), 
5.20 (d, 2H, J= 9.1 Hz), 4.16 (s, 2H). 3.68 (m, 1H), 3.59 (t, 2H, J= 5.8 Hz), 3.39 (m, 2H), 3.15 
(m, 2H), 2.75 (d, 3H, J= 9.1 Hz), 2.69 (t, 2H, J= 7.4 Hz), 2.54 (m, 1H), 2.19 (m, 1H), 1.75 (m, 
4H), 1.26 (s, 9H). 31P NMR (CDCl3) δ 9.3 (dd, J = 112, 94 Hz; minor), δ 9.5 (dd, J = 112, 94 Hz; 




















Procedure: Acid (80 mg 0.0707 mmol) 35 is dissolved in THF which had PyBop (0.036 mg, 
0.0707 mmol) added to it and allowed to react for 30 min.  While amine 29 (20 mg, 0.0355 
mmol) is dissolved in another portion of THF/DCM.  The two portions are added and allowed to 
react another 30 min.  Following this DIPEA (30 µg, 0.0707mmol) was added and the reaction 
proceeded 18 h.  The mixture was quenched with sat. NH4Cl (2 mL).  This was extracted with 
DCM (3x5 mL), concentrated, and purified by flash chromatography to afford 48e in a 62% yield 
as a dark yellow oil (17 mg, 0.022 mmol).  1H NMR (300 MHz, CDCl3) δ 9.30 (s, 1H, J= 1.0 Hz), 
8.62 (d, 1H, J= 6.0 Hz), 8.25 (d, 1H, J= 6.0 Hz), 8.08 (d, 1H, J=8.2 Hz), 8.96 (d, 1H, J= 7.2 Hz), 
7.62 (dd, 1H,  J= 8.2, 7.2 Hz), δ 7.44 (d, 1H, J= 3.7 Hz), 7.03 (d, 2H, J= 8.2 Hz), 7.00 (br-s, 1H, 
J= 5.2 Hz), 6.89 (d, 1H, J= 3.7 Hz), 6.70 (d, 2H, J= 8.3 Hz), 5.20 (d, 2H, J= 9.1 Hz), 4.00(s, 2H) 
3.68 (m, 1H), 3.59 (t, 2H, J= 5.8 Hz), 3.39 (m, 2H), 3.15 (m, 2H), 2.75 (d, 3H, J= 9.1 Hz), 2.69 (t, 
2H, J= 7.4 Hz), 2.54 (m, 1H), 2.19 (m, 1H), 1.75 (m, 4H) 31P NMR (CDCl3) δ 9.3 (dd, J= 112, 94 






















Procedure:  Acid (80 mg, 0.0707 mmol) 36 is dissolved in THF which had PyBop (0.073 mg, 
0.0707 mmol) added to it and allowed to react for 30 min.  While amine 29 (20 mg, 0.0355 
mmol) is dissolved in another portion of THF/DCM.  The two portions are added and allowed to 
react another 30 min.  Following this DIPEA (0.01 µg, 0.0707 mmol) was added and the reaction 
proceeded 18 h.  The mixture was quenched with sat. NH4Cl (2 mL).  This was extracted with 
DCM (3x5 mL), concentrated, and purified by flash chromatography to afford 48f in a 73% yield 
as a dark yellow oil (20 mg, 0.026mmol).  1H NMR (300 MHz, CDCl3) δ 8.97 (d, 1H, J= 4.1 Hz), 
8.80 (d, 1H, J= 8.5 Hz), 8.22 (d, 1H, J=1.4 Hz), 7.81 (t, 1H, J= 7.2, 1.4 Hz), 7.70 (d, 1H, J=7.2 
Hz), 7.48 (t, 1H, J= 8.6, 4.1 Hz), 7.44 (d, 1H, J= 3.7 Hz), 7.06 (br-s, 1H), 4.02 (s, 2H), 7.03 (d, 
2H, J= 8.2 Hz), 6.89 (d, 1H, J= 3.7 Hz), 6.70 (d, 2H, J= 8.3 Hz), 5.20 (d, 2H, J= 9.1 Hz), 3.68 
(m, 1H), 3.59 (t, 2H, J= 5.8 Hz), 3.39 (m, 2H), 3.15 (m, 2H), 2.75 (d, 3H, J= 9.1 Hz), 2.69 (t, 2H, 
J= 7.4 Hz), 2.54 (m, 1H), 2.19 (m, 1H), 1.75 (m, 4H) 31P NMR (CDCl3) δ 9.3 (dd, J= 112, 94 Hz; 






















Procedure:  Compound 48a (33 mg 0.038 mmol) is dissolved in formic acid 88% (20 eq) and 
stirred for 2 h.  The resulting solution is diluted with DCM/H2O and solid NaHCO3 is added until 
neutralization (pH 5-6).  The aqueous layer is extracted with DCM (5x5mL).  And the solution is 
purified by flash column chromatography resulting in the amine 48g with a yield of 37% as a 
dark yellow oil (11 mg 0.014 mmol).1H NMR (300 MHz, CDCl3) δ 8.45 (d, 1H, J= 8.4 Hz), 7.67 
(d, 1H, J= 7.5 Hz), 7.44 (d, 1H, J= 3.7 Hz), 7.28 (q, 1H, J= 8.9 Hz), 7.03 (d, 2H, J= 8.2 Hz), 6.82 
(br s, 1H), 6.70 (br d, 2H, J= 8.3 Hz), 5.20 (d, 2H, J= 9.1 Hz), 4.16 (s, 2H), 3.68 (m, 1H), 3.59 
(m, 4H), 3.55 (t, 2H, J= 8.6 Hz), 3.39 (m, 2H), 3.15 (m, 2H), 2.75 (d, 3H, J= 9.1 Hz), 2.69 (t, 2H, 
J= 7.4 Hz), 2.54 (m, 1H), 2.19 (m, 1H), 1.75 (m, 4H), 1.16 (s, 9H) 31P NMR (CDCl3) δ 9.3 (dd, 




















Procedure:  Compound 48d (53 mg, 0.062 mmol) is dissolved in formic acid 88% (20 eq) and 
stirred for 2 h.  The resulting solution is diluted with DCM/H2O and solid NaHCO3 is added until 
neutralization (pH 5-6).  The aqueous layer is extracted with DCM (5x5 mL).  And the solution is 
purified by flash column chromatography resulting in the amine 48h with a yield of 42% as a 
dark yellow oil (20 mg, 0.026 mmol).1H NMR (300 MHz, CDCl3) δ 7.93 (d, 1H, J= 4.9 Hz), 7.92 
(d, 1H, J= 4.9 Hz), 7.63 (d, 1H, J= 3.2 Hz), 7.44 (d, 1H, J= 3.7 Hz), 7.27 (d, 1H, J= 3.2 Hz), 7.18 
(t, 1H, J= 5.2 Hz), 7.23 (d, 2H, J= 8.2 Hz), 6.94 (br s, 1H), 6.30 (d, 2H, J= 8.3 Hz), 5.20 (d, 2H, 
J= 9.1 Hz), 4.16 (s, 2H). 3.68 (m, 1H), 3.59 (t, 2H, J= 5.8 Hz), 3.39 (m, 2H), 3.15 (m, 2H), 2.75 
(d, 3H, J= 9.1 Hz), 2.69 (t, 2H, J= 7.4 Hz), 2.54 (m, 1H), 2.19 (m, 1H), 1.75 (m, 4H) 31P NMR 
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